Publications in collaboration with researchers from Hospital Universitario La Paz (22)

2024

  1. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study

    Journal of Global Antimicrobial Resistance, Vol. 36, pp. 200-209

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

  2. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

  3. Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

2020

  1. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

    Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1

  2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    The Lancet, Vol. 393, Núm. 10167, pp. 143-155

2018

  1. Antibiotic selection in the treatment of acute invasive infections by pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy

    Revista Espanola de Quimioterapia, Vol. 31, Núm. 1, pp. 78-100

  2. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

    PLoS ONE, Vol. 13, Núm. 4

  3. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT

    Revista Espanola de Quimioterapia, Vol. 27, Núm. 2, pp. 93-97

2012

  1. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

    Farmacia Hospitalaria, Vol. 36, Núm. 1

  2. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 30, Núm. 1

2011

  1. Programs to optimize antimicrobial use (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document

    Medicina Preventiva, Vol. 17, Núm. 3, pp. 29-39

2009

  1. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

    AIDS, Vol. 22, Núm. 2